MX2022004209A - Formas cristalinas de estado solido de un modulador selectivo de canales de potasio. - Google Patents

Formas cristalinas de estado solido de un modulador selectivo de canales de potasio.

Info

Publication number
MX2022004209A
MX2022004209A MX2022004209A MX2022004209A MX2022004209A MX 2022004209 A MX2022004209 A MX 2022004209A MX 2022004209 A MX2022004209 A MX 2022004209A MX 2022004209 A MX2022004209 A MX 2022004209A MX 2022004209 A MX2022004209 A MX 2022004209A
Authority
MX
Mexico
Prior art keywords
solid state
potassium channel
crystalline forms
channel modulator
selective potassium
Prior art date
Application number
MX2022004209A
Other languages
English (en)
Inventor
Gregory N Beatch
Paul Robert Bichler
Jean - Jacques A Cadieux
Matthew David Tandy
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of MX2022004209A publication Critical patent/MX2022004209A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Laminated Bodies (AREA)
  • Liquid Crystal Substances (AREA)
  • Transmitters (AREA)

Abstract

La presente descripción proporciona formas de estado sólido de un modulador selectivo de los canales de potasio y composiciones farmacéuticas que comprenden las formas cristalinas de estado sólido y excipientes farmacéuticamente aceptables, y métodos para preparar y usar las formas de estado sólido y sus composiciones farmacéuticas.
MX2022004209A 2019-10-10 2020-10-09 Formas cristalinas de estado solido de un modulador selectivo de canales de potasio. MX2022004209A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962913574P 2019-10-10 2019-10-10
PCT/US2020/055129 WO2021072307A1 (en) 2019-10-10 2020-10-09 Solid state crystalline forms of a selective potassium channel modulator

Publications (1)

Publication Number Publication Date
MX2022004209A true MX2022004209A (es) 2022-05-03

Family

ID=73040296

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004209A MX2022004209A (es) 2019-10-10 2020-10-09 Formas cristalinas de estado solido de un modulador selectivo de canales de potasio.

Country Status (17)

Country Link
US (2) US11091441B2 (es)
EP (1) EP4041713A1 (es)
JP (1) JP2022552187A (es)
KR (1) KR20220080119A (es)
CN (1) CN115190874A (es)
AU (1) AU2020364142A1 (es)
BR (1) BR112022006583A2 (es)
CA (1) CA3153752A1 (es)
CL (1) CL2022000881A1 (es)
CO (1) CO2022005890A2 (es)
CR (1) CR20220187A (es)
IL (1) IL292005A (es)
MA (1) MA56288A1 (es)
MX (1) MX2022004209A (es)
PE (1) PE20221023A1 (es)
TW (1) TW202128627A (es)
WO (1) WO2021072307A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL304920A (en) 2021-02-09 2023-10-01 Xenon Pharmaceuticals Inc A voltage-gated potassium channel opener for use in the treatment of anhedonia
CN113698345B (zh) * 2021-10-27 2022-02-01 上海挚盟医药科技有限公司 作为钾通道调节剂的化合物及其制备和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
AU2007288253B2 (en) * 2006-08-23 2013-05-02 Xenon Pharmaceuticals Inc. Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
KR20210020892A (ko) 2018-05-11 2021-02-24 제논 파마슈티칼스 인크. 전압 의존형 칼륨 채널 개방제의 생체 이용률 및 노출을 향상시키는 방법

Also Published As

Publication number Publication date
TW202128627A (zh) 2021-08-01
WO2021072307A1 (en) 2021-04-15
PE20221023A1 (es) 2022-06-16
CO2022005890A2 (es) 2022-05-31
AU2020364142A1 (en) 2022-04-21
IL292005A (en) 2022-06-01
US11091441B2 (en) 2021-08-17
KR20220080119A (ko) 2022-06-14
CA3153752A1 (en) 2021-04-15
MA56288A1 (fr) 2023-01-31
EP4041713A1 (en) 2022-08-17
BR112022006583A2 (pt) 2022-06-28
US20220064120A1 (en) 2022-03-03
CR20220187A (es) 2022-07-21
CL2022000881A1 (es) 2023-01-13
CN115190874A (zh) 2022-10-14
JP2022552187A (ja) 2022-12-15
US20210147363A1 (en) 2021-05-20

Similar Documents

Publication Publication Date Title
AU2018271990A1 (en) Covalent inhibitors of KRAS
AU2018351533A8 (en) Crystalline forms and compositions of CFTR modulators
MX2019001308A (es) Moduladores nmda espiro-lactam y metodos de uso de los mismos.
MX2018006800A (es) Composicion farmaceutica.
PH12021550048A1 (en) Selective estrogen receptor degraders.
PH12019501639A1 (en) Jaki selective inhibitors
PH12017502376B1 (en) Oral solid formulation containing irinotecan and method of preparing the same
MX2022004209A (es) Formas cristalinas de estado solido de un modulador selectivo de canales de potasio.
MX2020011756A (es) Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo.
PH12021550413A1 (en) Vitamin d pediatric dosage forms, methods of making and using
MX2021007247A (es) Derivados de rapamicina.
TR201721505A2 (tr) Li̇nagli̇pti̇n ve metformi̇n i̇çeren kombi̇nasyon
PH12019501678A1 (en) Potassium channel modulators
EP4081746A4 (en) SUBSTANTIALLY SOLID SOLUTION, SYSTEMS AND METHODS FOR PRODUCING A SUBSTANTIALLY SOLID SOLUTION AND METHODS FOR ADMINISTRATION THEREOF
PH12021550439A1 (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
MX2022000287A (es) Composición de inhibidor micromolécular de pi4kiiia, método de preparación y uso.
EP3978478A4 (en) TETRAHYDRO-1H-BENZAZEPINE COMPOUND AS A POTASSIUM CHANNEL MODULATOR, ITS PREPARATION PROCESS AND USE
EP3459933A3 (en) Solid forms of a pharmaceutically active compound
WO2018119108A8 (en) Solid pharmaceutical formulations of asimadoline
AU2016335960A8 (en) Methods and formulations for reducing bovine emissions
MX2019015869A (es) Nuevas formulaciones orales de belinostat.
MX2021001043A (es) Composiciones para el tratamiento de hipertension.
ZA202105718B (en) Novel composition
MX2018007326A (es) Composicion para reducir la frecuencia de miccion, metodo para elaborar y utilizar la misma.
MX2021016044A (es) Composiciones de diclorfenamida y metodos de uso.